GeneDx Holdings Corp. (WGS)
- Previous Close
11.17 - Open
11.21 - Bid 11.04 x 100
- Ask 11.16 x 100
- Day's Range
10.81 - 11.56 - 52 Week Range
1.16 - 12.57 - Volume
148,884 - Avg. Volume
202,811 - Market Cap (intraday)
288.674M - Beta (5Y Monthly) 2.82
- PE Ratio (TTM)
-- - EPS (TTM)
-7.23 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.38
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
www.genedx.com1,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: WGS
Performance Overview: WGS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WGS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WGS
Valuation Measures
Market Cap
288.67M
Enterprise Value
278.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.33
Price/Book (mrq)
1.27
Enterprise Value/Revenue
1.37
Enterprise Value/EBITDA
-2.04
Financial Highlights
Profitability and Income Statement
Profit Margin
-86.77%
Return on Assets (ttm)
-23.37%
Return on Equity (ttm)
-72.97%
Revenue (ttm)
202.57M
Net Income Avi to Common (ttm)
-175.77M
Diluted EPS (ttm)
-7.23
Balance Sheet and Cash Flow
Total Cash (mrq)
130.15M
Total Debt/Equity (mrq)
52.53%
Levered Free Cash Flow (ttm)
-124.84M